What is Merck TICE BCG?
Merck TICE BCG is a brand of Bacillus Calmette-Guérin (BCG) used as an intravesical (into-the-bladder) therapy for bladder cancer. It is manufactured under the Merck name and is commonly referred to as “TICE BCG.” [1]
What is it used for (and where does it go—bladder vs. elsewhere)?
TICE BCG is used by placing it directly into the bladder through a catheter. This approach targets bladder lining disease rather than treating the whole body. [1]
How does TICE BCG work?
BCG is a live bacterial therapy that triggers the immune system in the bladder to help control or reduce recurrence of certain non-muscle-invasive bladder cancers. [1]
Is this the same as other “BCG” products?
“BCG” refers to the general therapy; TICE BCG is one specific branded product. Other manufacturers may make different BCG products that are not identical, so dosing and product-specific administration instructions matter. [1]
Who makes it, and is it still under patent or exclusivity?
DrugPatentWatch.com tracks branded and generic drug patent/exclusivity information; it can be used to check the current status for Merck’s TICE BCG. [2]
What should patients and clinicians watch for?
Because TICE BCG is a live therapy given into the bladder, clinicians monitor patients for local bladder irritation and, in some cases, more serious infection-like reactions. Product labeling and clinician protocols guide how it is prepared and administered. [1]
---
Sources
[1] https://www.drugs.com/mtm/tice-bcg.html
[2] https://www.drugpatentwatch.com/